What Is A Calr Mutation Causes Testing And Prognosis?

A CALR mutation is a change in the CALR gene that alters how the body makes a protein called calreticulin. This mutation is found in most people who have two related bone marrow conditions: essential thrombocythemia and primary myelofibrosis. It is not inherited from a parent. It develops during a person’s lifetime in a single blood-forming cell, and testing for it has become a standard step in diagnosing certain blood disorders.

What Is a CALR Mutation and What Does It Do?

The CALR gene carries the instructions for making calreticulin. This protein lives inside cells and helps fold other proteins and manage calcium. It also sits in a part of the cell called the endoplasmic reticulum, where much of a cell’s protein processing happens.

The mutations found in blood disorders are almost always in one specific stretch of the gene. They are small insertions or deletions, not the kind of large gene damage seen in some cancers. The result is a calreticulin protein with a changed tail end. That altered protein moves to different places in the cell than it normally would.

Researchers have shown that the mutant protein interacts with a receptor on blood-forming cells called MPL. This interaction switches on signaling pathways that tell the cell to keep growing and dividing. That is the leading explanation for why these mutations drive excess blood cell production.

The key point is that a CALR mutation is a somatic mutation. It happens in a single cell after birth, not in the egg or sperm. So it cannot be passed to children. This is different from mutations people inherit, like the BRCA changes linked to breast and ovarian cancer risk.

What Causes a CALR Mutation?

No one knows what triggers the mutation. There is no confirmed environmental exposure, lifestyle habit, or inherited factor that has been shown to cause it.

What is known is the mechanism. The mutation arises in a hematopoietic stem cell in the bone marrow. That stem cell then passes the mutation to all the blood cells it produces. This is why the mutation can be detected in blood samples.

Some people ask whether radiation, chemicals, or stress cause these mutations. The honest answer is that no study has confirmed any of these as a cause. The mutation appears to be a random event in most cases.

CALR mutations belong to a group called driver mutations. These are mutations that give a blood cell a growth advantage. The other main drivers in these conditions are JAK2 and MPL mutations. In most patients, only one driver mutation is present. Finding one does not rule out the others, but it does help classify the disease.

What Conditions Are Linked to CALR Mutations?

CALR mutations are found mainly in two conditions. The first is essential thrombocythemia, where the bone marrow makes too many platelets. The second is primary myelofibrosis, where scar tissue builds up in the bone marrow and blood cell production gets disrupted.

In essential thrombocythemia, CALR mutations are found in roughly a quarter to a third of patients. In primary myelofibrosis, the range is similar. These conditions are known as myeloproliferative neoplasms, a group of disorders where the bone marrow makes too many of certain blood cells.

The table below shows how the three main driver mutations compare in these conditions.

These figures are approximate because different studies report slightly different ranges. What matters is that CALR is one of the two most common drivers.

CALR mutations are very rarely seen in other types of cancer or blood disease. So when one is found, it strongly points toward a myeloproliferative neoplasm.

How Is CALR Mutation Testing Done?

Testing is done on a blood sample in most cases. Sometimes a bone marrow sample is used. The test looks for the specific insertions and deletions in the CALR gene.

There are a few methods labs use. One common approach is polymerase chain reaction, which can detect the mutation quickly. Another is next-generation sequencing, which reads the gene in more detail and can find mutations that other methods might miss.

Testing is usually ordered when a person has unexplained high platelet counts, an enlarged spleen, or other signs of a myeloproliferative neoplasm. Doctors often test for JAK2 and MPL at the same time. If all three are negative, a doctor may still consider these conditions based on other findings, because a small number of cases have no identifiable driver mutation.

One practical point: the mutation is present in the blood, so a simple blood draw is often enough. A bone marrow biopsy may still be needed to see how the marrow looks and to help tell essential thrombocythemia apart from primary myelofibrosis.

What Does a CALR Mutation Mean for Prognosis?

For essential thrombocythemia, several studies have found that patients with a CALR mutation tend to have a lower risk of blood clots and a lower risk of progression to more serious disease compared with patients who have a JAK2 mutation. This is one of the more consistent findings in the field.

For primary myelofibrosis, the picture is more nuanced. Some research indicates that CALR-mutated cases may have a somewhat better outlook than JAK2-mutated cases, but the evidence is less uniform. Prognosis in myelofibrosis depends heavily on other factors too, including age, blood counts, and the degree of bone marrow scarring.

It is important not to read too much into the mutation alone. Prognosis is shaped by many things. A doctor looks at the whole picture, not just one test result.

What is clear is that CALR status has become a useful piece of information. It helps confirm the diagnosis and, in some cases, helps guide how closely a patient is monitored.

How Are CALR-Mutated Conditions Treated?

Treatment depends on the specific condition and the person’s risk level, not on the mutation itself. There are no therapies approved specifically for CALR-mutated disease.

For essential thrombocythemia, treatment often focuses on lowering the risk of clots. Options include low-dose aspirin and, for higher-risk patients, medications that reduce platelet counts. Hydroxyurea is commonly used. Anagrelide is another option. Some patients, especially younger ones, may be watched without treatment if their risk is low.

For primary myelofibrosis, treatment is more complex. It may include medications that target the JAK2 pathway, even in patients without a JAK2 mutation, because these drugs affect broader signaling. Other options include drugs that suppress the immune system, blood transfusions, and in some cases stem cell transplant, which is the only treatment that can potentially cure the disease.

Some clinicians have explored whether the mutant calreticulin protein itself could be a drug target. Research is ongoing. No treatment that directly targets the mutant protein is currently approved for routine use.

Anyone with these conditions should work with a hematologist. The right approach depends on age, symptoms, blood counts, and other health factors.

What Should You Do If You Have a CALR Mutation?

First, understand that finding this mutation is not a reason to panic. It is a piece of diagnostic information. Many people with CALR-mutated essential thrombocythemia live for decades with the condition and manage it with relatively simple treatment.

Second, make sure you are being seen by a specialist. A hematologist can confirm the diagnosis, assess your risk, and recommend monitoring or treatment as needed.

Third, ask questions. What condition do I have? What is my risk level? What symptoms should I watch for? What are my treatment options? These are reasonable questions and a good doctor will answer them.

There is no diet, supplement, or lifestyle change that has been shown to reverse or cure a CALR mutation. Be cautious of anyone who claims otherwise.